Mifepristone and sublingual misoprostol versus sublingual misoprostol alone for missed abortion: Results of a randomized placebo-controlled trial
- May 4th, 2019
- Staff Publication
- Medical Abortion
- Bracken, H., Zuberi, N., de Guevara Puerto, A.L., Mayi-Tsonga, S., Buendía Gómez, M., Irfan Ahmed, S., Minkobame, U., Perrin, R.X., Diop, A., Abbas, D., Pena, M., Winikoff, B.
Introduction: Medical management of missed abortion has been demonstrated to be a safe and effective alternative to uterine aspiration. Regimens for medical management subjected to clinical trials using pretreatment with mifepristone followed by misoprostol have generally employed vaginal misoprostol. However, misoprostol-only regimens recommended by the World Health Organization also include sublingual misoprostol. We compared the efficacy and safety of pretreatment with mifepristone followed by sublingual misoprostol with the efficacy and safety of sublingual misoprostol alone for the management of missed abortion.
Access the abstract.